Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?

References

• Parisi R, Symmons DP, Griffiths CE, et al. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385. doi:10.1038/jid.2012.33923014338
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–271. doi:10.1016/S0140-6736(07)61128-317658397
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407. doi:10.1016/S0190-9622(99)70112-X10459113
   PubMed Web of Science ®Google Scholar
• Smith CH, Barker JN. Psoriasis and its management. Bmj. 2006;333:380–384. doi:10.1136/bmj.333.7564.38016916825
   PubMed Web of Science ®Google Scholar
• Shahwan KT, Kimball AB. Psoriasis and cardiovascular disease. Med Clin North Am. 2015;99:1227–1242. doi:10.1016/j.mcna.2015.08.00126476250
   PubMed Web of Science ®Google Scholar
• Miller IM, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69:1014–1024. doi:10.1016/j.jaad.2013.06.05324238156
   PubMed Web of Science ®Google Scholar
• Huerta C, Rivero E, Garcia Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143:1559–1565. doi:10.1001/archderm.143.12.155918087008
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509. doi:10.1056/NEJMra080459519641206
   PubMed Web of Science ®Google Scholar
• Péter I, Jagicza A, Ajtay Z, et al. Psoriasis and oxidative stress. Orv Hetil. 2016;157:1781–1785. doi:10.1556/650.2016.3058927817235
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol. 2010;24:789–796. doi:10.1111/j.1468-3083.2009.03527.x20002653
   PubMed Web of Science ®Google Scholar
• Vadakayil AR, Dandekeri S, Kambil SM, et al. Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol Online J. 2015;6:322–325. doi:10.4103/2229-5178.16448326500861
   PubMedGoogle Scholar
• Isha Jain VK, Lal H. C-reactive protein and uric acid levels in patients with psoriasis. Indian J Clin Biochem. 2011;26:309–311. doi:10.1007/s12291-011-0132-422754198
   PubMedGoogle Scholar
• Vanizor Kural B, Orem A, Cimşit G, et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta. 2003;328:71–82.12559600
   PubMed Web of Science ®Google Scholar
• Dowlatshahi EA, van der Voort EA, Arends LR, et al. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169:266–282. doi:10.1111/bjd.1235523550658
   PubMed Web of Science ®Google Scholar
• Németh B, Kustán P, Németh Á, et al. Asymmetric dimethylarginine: predictor of cardiovascular diseases? Orv Hetil. 2016;157:483–487. doi:10.1556/650.2016.3039626996894
   PubMed Web of Science ®Google Scholar
• Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation. 2004;109:1813–1818. doi:10.1161/01.CIR.0000126823.07732.D515096461
   PubMed Web of Science ®Google Scholar
• Németh B, Ajtay Z, Hejjel L, et al. The issue of plasma asymmetric dimethylarginine reference range - A systematic review and meta-analysis. PLoS One. 2017;12:e0177493. doi:10.1371/journal.pone.017749328494019
   PubMed Web of Science ®Google Scholar
• Bilgiç Ö, Altınyazar HC, Baran H, et al. Serum homocysteine, asymmetric dimethyl arginine (ADMA) and other arginine– NO pathway metabolite levels in patients with psoriasis. Arch Dermatol Res. 2015;307:439–444. doi:10.1007/s00403-015-1553-325708188
   PubMed Web of Science ®Google Scholar
• Relhan V, Gupta SK, Dayal S, et al. Blood thiols and malondialdehyde levels in psoriasis. J Dermatol. 2002;29:399–403.12184635
   PubMed Web of Science ®Google Scholar
• Kadam DP, Suryakar AN, Ankush RD, et al. Role of oxidative stress in various stages of psoriasis. Indian J Clin Biochem. 2010;25:388–392. doi:10.1007/s12291-010-0043-921966111
   PubMedGoogle Scholar
• Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858–6862. doi:10.1073/pnas.78.11.68586947260
   PubMed Web of Science ®Google Scholar
• Fabbrini E, Serafini M, Colic Baric I, et al. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes. 2014;63:976–981. doi:10.2337/db13-139624353177
   PubMed Web of Science ®Google Scholar
• Li X, Miao X, Wang H, et al. Association of serum uric acid levels in psoriasis: a systematic review and meta-analysis. Medicine. 2016;95:e3676. doi:10.1097/MD.000000000000486427175702
   PubMed Web of Science ®Google Scholar
• Gabr SA, Al-Ghadir AH. Role of cellular oxidative stress and cytochrome C in the pathogenesis of psoriasis. Arch Dermatol Res. 2012;304:451–457. doi:10.1007/s00403-011-1171-722421888
   PubMed Web of Science ®Google Scholar
• Hashemi M, Mehrabifar H, Daliri M, et al. Adenosine deaminase activity, trypsin inhibitory capacity and total antioxidant capacity in psoriasis. J Eur Acad Dermatol Venereol. 2010;24:329–334. doi:10.1111/j.1468-3083.2009.03416.x19732251
   PubMed Web of Science ®Google Scholar
• Lin X, Huang T. Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radic Res. 2016;50:585–595. doi:10.3109/10715762.2016.116230127098416
   PubMed Web of Science ®Google Scholar
• Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta. 2000;1482:157–171.11058758
   PubMed Web of Science ®Google Scholar
• Ceciliani F, Pocacqua V. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr Protein Pept Sci. 2007;8:91–108.17305563
   PubMed Web of Science ®Google Scholar
• Kustán P, Szirmay B, Kőszegi T, et al. Monitoring urinary orosomucoid in patients undergoing cardiac surgery: a promising novel inflammatory marker. Clin Biochem. 2017;17:pii:S0009–9120 30445–304459.
   Google Scholar
• Biljan D, Situm M, Kostović K, et al. Acute phase proteins in psoriasis. Coll Antropol. 2009;33:83–86.19408608
   PubMed Web of Science ®Google Scholar
• Li F, Yu Z, Chen P, et al. The increased excretion of urinary orosomucoid 1 as a useful biomarker for bladder cancer. Am J Cancer Res. 2016;6:331–340.27186407
   PubMed Web of Science ®Google Scholar
• Hou LN, Li F, Zeng QC, et al. Excretion of urinary orosomucoid 1 protein is elevated in patients with Chronic Heart Failure. PLoS One. 2014;9:e107550. doi:10.1371/journal.pone.010755025215505
   PubMed Web of Science ®Google Scholar
• Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. Bmj. 2010;340:c2442. doi:10.1136/bmj.c29320466793
   PubMed Web of Science ®Google Scholar
• Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210:194–199. doi:10.1159/00008350915785046
   PubMed Web of Science ®Google Scholar
• Martens-Lobenhoffer J, Bode-Böger SM. Quantification of L-arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma: a step improvement in precision by stable isotope dilution mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;904:140–143. doi:10.1016/j.jchromb.2012.07.021
   PubMed Web of Science ®Google Scholar
• Kustán P, Szirmay B, Horváth-Szalai Z, et al. Urinary orosomucoid: validation of an automated immune turbidimetric test and its possible clinical use. Biochem Med. 2016;26:421–430. doi:10.11613/BM.2016.044
   PubMed Web of Science ®Google Scholar
• Kőszegi T, Sali N, Raknić M, et al. A novel luminol-based enhanced chemiluminescence antioxidant capacity microplate assay for use in different biological matrices. J Pharmacol Toxicol Methods. 2017;88:153–159. doi:10.1016/j.vascn.2017.09.25628962917
   PubMed Web of Science ®Google Scholar
• González-Gay MA, González-Vela C, González-Juanatey C. Psoriasis: a skin disease associated with increased cardiovascular risk. Actas Dermosifiliogr. 2012;103:595–598. doi:10.1016/j.ad.2012.01.00622465257
   PubMedGoogle Scholar
• Shaharyar S, Warraich H, McEvoy JW, et al. Subclinical cardiovascular disease in plaque psoriasis: association or causal link? Atherosclerosis. 2014;232:72–78. doi:10.1016/j.atherosclerosis.2013.10.02324401219
   PubMed Web of Science ®Google Scholar
• Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124:775.e1–775.e6. doi:10.1016/j.amjmed.2011.03.028
   Web of Science ®Google Scholar
• Garg N, Muduli SK, Kapoor A, et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J. 2017;69:458–463. doi:10.1016/j.ihj.2017.01.01528822511
   PubMedGoogle Scholar
• Zhou Q, Mrowietz U, Rostami-Yazdi M, et al. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med. 2009;47:891–905. doi:10.1016/j.freeradbiomed.2009.06.03319577640
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci. 2009;55:202–204. doi:10.1016/j.jdermsci.2009.05.00819576730
   PubMed Web of Science ®Google Scholar
• Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol. 2004;18:180.15009298
   PubMed Web of Science ®Google Scholar
• Kustán P, Kőszegi T, Miseta A, et al. Urinary orosomucoid a potential marker of inflammation in psoriasis. Int J Med Sci. 2018;15:1113–1117. doi:10.7150/ijms.2568730123048
   PubMed Web of Science ®Google Scholar
• El-Beblawy NM, Andrawes NG, Ismail EA, et al. Serum and urinary orosomucoid in young patients with type 1 diabetes: a link between inflammation, microvascular complications, and subclinical atherosclerosis. Clin Appl Thromb Hemost. 2016;22:718–726. doi:10.1177/107602961663718526975878
   PubMed Web of Science ®Google Scholar
• Christiansen MS, Iversen K, Larsen CT, et al. Increased urinary orosomucoid excretion: a proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes. Scand J Clin Lab Invest. 2009;69:272–281. doi:10.1080/0036551080253110018972260
   PubMed Web of Science ®Google Scholar